SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study
Background SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a candidate contributor to airway inflammation and remodeling. We explored associations between the SERPINE1 −675 4G/5G polymorphism and outcomes during tezepelumab treatment. Methods This prospective multicenter cohort enrolled 45 Japanese adults; 44 completed 52 weeks (4G/4G, 21; 4G/5G, 15; 5G/5G, 8). Genotyping of pretreatment samples occurred after follow-up, with physicians and outcome assessors blinded to genotype. The approved protocol specified negative binomial regression comparing 4G carriers with 5G/5G, adjusted for prior-year exacerbations. Additional adjustment for prior biologic exposure, ICS category, and maintenance OCS use was retained as exploratory. Results Forty-seven exacerbations occurred over 44 patient-years, defining one analysis year as 52 weeks. Crude annualized exacerbation rates were 1.14, 0.73, and 1.50 events/patient-year across the three genotypes; 30 participants had no exacerbations. The protocol-specified adjusted incidence rate ratio was 5.06 (95% confidence interval, 0.51–49.97), compared with 0.65 (0.11–3.69) unadjusted and 3.28 (0.34–31.29) with expanded adjustment. These estimates were too imprecise and model-dependent for reliable interpretation. An exploratory three-genotype FeNO comparison at week 52 yielded P = 0.00353; post hoc false discovery rate adjustment gave q = 0.04594 across 13 secondary tests and q = 0.08127 across 23 secondary/exploratory tests. The 0.05 threshold was met only in the smaller family; both adjustments remain exploratory. Conclusions The data do not establish either a clinically useful genotype association or its absence. Sparse outcomes, baseline imbalance, and heterogeneous treatment histories limit inference. Without a comparator treatment, this study cannot determine whether genotype modifies the treatment effect of tezepelumab. Trial registration: UMIN000052531, October 18, 2023.
Authors
- Hiromi Ide (ORCID: https://orcid.org/0000-0001-5619-5706)
- Norio Kodaka (ORCID: https://orcid.org/0000-0003-1833-6832)
- 和子 山本
- Shusaku Haranaga
- Wakako Arakaki
- Hironobu Tsubouchi (ORCID: https://orcid.org/0000-0003-3267-0730)
- Nobuhiro Matsumoto (ORCID: https://orcid.org/0000-0001-5581-5635)
- Ayako Matsuo
- 慎也 泊
- Hiroki Tashiro (ORCID: https://orcid.org/0000-0001-9699-414X)
- Nobuko Matsuo
- Hideki Sakakibara
- Chizu Fukushima
- Koichiro Takahashi
- Kazunori Tobino
- Kosuke Kosai
- Katsunori Yanagihara
- Hiroto Matsuse
- Kazuhiro Yatera
- Hiroshi Mukae
- Taiga Miyazaki
- Susumu Fukahori
- Daisuke Himeji
- Hiroyuki Yoshimine
- Yasushi Obase
- Shintaro Hara
Institutions
- University of Miyazaki (JP)
- Saga University (JP)
- University of Occupational and Environmental Health Japan (JP)
- University of the Ryukyus (JP)
- Inoue Hospital (JP)
- Toho University Ohashi Medical Center (JP)
- Miyazaki Prefectural Hospital (JP)
- Nagasaki Medical Center (JP)
- Japan Community Healthcare Organization (JP)
- National Hospital Organization Miyazaki Higashi Hospital (JP)
- Aso Iizuka Hospital (JP)
- University of the Ryukyus University Hospital (JP)
- Nagasaki University Hospital (JP)
- Nagasaki University (JP)
- Isahaya General Hospital (JP)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/falgy.2026.2016157
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00